Show simple item record

dc.contributor.authorMalicki, Stanislawen_US
dc.contributor.authorKsiazek, Miroslawen_US
dc.contributor.authorMajewski, Pawelen_US
dc.contributor.authorPecak, Aleksandraen_US
dc.contributor.authorMydel, Piotr Mateuszen_US
dc.contributor.authorGrudnik, Przemyslawen_US
dc.contributor.authorDubin, Grzegorzen_US
dc.PublishedMalicki S, Ksiazek, Majewski, Pecak, Mydel PM, Grudnik, Dubin. Development of a novel, high-affinity ssDNA trypsin inhibitor. Journal of enzyme inhibition and medicinal chemistry (Print). 2019;34(1):638-643eng
dc.description.abstractInhibitors of serine proteases are not only extremely useful in the basic research but are also applied extensively in clinical settings. Using Systematic Evolution of Ligands by Exponential Enrichment (SELEX) approach we developed a family of novel, single-stranded DNA aptamers capable of specific trypsin inhibition. Our most potent candidate (T24) and its short version (T59) were thoroughly characterised in terms of efficacy. T24 and T59 efficiently inhibited bovine trypsin with Ki of 176 nM and 475 nM, respectively. Interestingly, in contrast to the majority of known trypsin inhibitors, the selected aptamers have superior specificity and did not interact with porcine trypsin or any human proteases tested. These included plasmin and thrombin characterised by trypsin-like substrate specificity. Our results demonstrate that SELEX may be successfully employed in the development of potent and specific DNA based protease inhibitors.en_US
dc.publisherTaylor & Franciseng
dc.rightsAttribution CC BYeng
dc.titleDevelopment of a novel, high-affinity ssDNA trypsin inhibitoren_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Author(s)
dc.source.journalJournal of enzyme inhibition and medicinal chemistry (Print)

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY